Suvorexant for insomnia in patients with psychiatric disorder: A 1‐week, open‐label study
Abstract Aim There have been no previous reports on the efficacy and safety of suvorexant for insomnia in people with psychiatric disorders. Methods This one‐week, prospective, single‐arm, clinical trial of fixed dose of suvorexant (20 mg if ages 18–64 or 15 mg if age ≥ 65 years) for insomnia includ...
| المؤلفون الرئيسيون: | , , , , , , , , , , |
|---|---|
| التنسيق: | مقال |
| اللغة: | English |
| منشور في: |
Wiley
2019-09-01
|
| سلاسل: | Neuropsychopharmacology Reports |
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://doi.org/10.1002/npr2.12069 |